Literature DB >> 25272338

Antidepressants in bipolar I disorder: never as monotherapy.

Eduard Vieta.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25272338     DOI: 10.1176/appi.ajp.2014.14070826

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  5 in total

1.  Bipolar II Disorder: Frequent, Valid, and Reliable.

Authors:  Eduard Vieta
Journal:  Can J Psychiatry       Date:  2019-08       Impact factor: 4.356

Review 2.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 3.  Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention.

Authors:  Erica Bell; Phil Boyce; Richard J Porter; Richard A Bryant; Gin S Malhi
Journal:  CNS Drugs       Date:  2021-05-21       Impact factor: 5.749

4.  Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision.

Authors:  Young Sup Woo; Won-Myong Bahk; Jung Goo Lee; Jong-Hyun Jeong; Moon-Doo Kim; InKi Sohn; Se-Hoon Shim; Duk-In Jon; Jeong Seok Seo; Kyung Joon Min; Won Kim; Hoo-Rim Song; Bo-Hyun Yoon
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-11-30       Impact factor: 2.582

Review 5.  The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research.

Authors:  Konstantinos N Fountoulakis; Eduard Vieta; Allan Young; Lakshmi Yatham; Heinz Grunze; Pierre Blier; Hans Jurgen Moeller; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.